We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BZU:MILBuzzi Spa Analysis

Data as of 2026-06-11 - not real-time

€44.02

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Buzzi S.p.A. (BZU.MI) is trading at €44.02, comfortably below its 20‑day (≈44.37), 50‑day (≈46.01) and 200‑day (≈48.00) simple moving averages, signaling a short‑term bearish bias. The RSI sits at 44, just under the neutral threshold, while the MACD histogram remains negative, reinforcing the down‑trend. Despite the technical weakness, the stock boasts a low trailing P/E of 8.65 and a modest price‑to‑book of 1.12, indicating cheap earnings relative to peers. However, the discounted cash‑flow model places intrinsic value at only about €27.6, well beneath the market price, suggesting the market may be pricing in growth expectations beyond current fundamentals.
Fundamentally, Buzzi delivers solid profitability with a 20.4% profit margin and a healthy operating cash flow of €914 M, supported by a strong cash pile (€1.4 B) that exceeds its total debt (€441 M). The dividend yield of 1.59% is underpinned by a low payout ratio (~13.8%), making the payout sustainable. Analysts remain optimistic, targeting a median price of €54, implying roughly 20% upside, and the consensus recommendation is a “buy”. The company’s diversified presence across Europe, North America, the Middle East and Latin America adds geographic breadth, while volatility remains elevated at ~32% over the past month, albeit with a low beta (~0.47) indicating limited market‑wide correlation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price below key moving averages and bearish MACD
  • decreasing trading volume reducing near‑term liquidity
  • proximity to support level around €42.44

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • low P/E and P/B ratios indicating value appeal
  • strong cash generation and low debt‑to‑equity profile
  • analyst price targets suggesting ~20% upside

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • stable dividend with sustainable payout ratio
  • diversified geographic footprint mitigating single‑market risk
  • consistent profitability margins and solid ROE (~13%)

Key Metrics & Analysis

Financial Health

Revenue Growth2.90%
Profit Margin20.35%
P/E Ratio8.6
ROE13.44%
ROA6.30%
Debt/Equity6.18
P/B Ratio1.1
Op. Cash Flow€914.1M
Free Cash Flow€265.1M

Technical Analysis

TrendBearish
RSI44.0
Support€42.44
Resistance€47.18
MA 20€44.37
MA 50€46.01
MA 200€48.00
MACDBearish
VolumeDecreasing
Fear & Greed Index83.82

Valuation

Fair Value€27.57
Target Price€53.16
Upside/Downside20.76%
GradeFair
TypeBlend
Dividend Yield1.59%

Risk Assessment

Beta0.47
Volatility31.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.